ReviewCancers2026
Intraoperative Spectroscopic and Mass Spectrometric Assessment of Glioma Margins: A Systematic Review and Meta-Analysis.
Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMaximal safe resection remains a central determinant of outcomes in glioma surgery, yet intraoperative discrimination between tumor and normal brain tissue is limited by the speed and subjectivity of frozen-section analysis. Label-free techniques such as Raman spectroscopy, mass spectrometry (MS), and optical coherence tomography (OCT) offer real-time biochemical and structural characterization that may enhance surgical precision. Their comparative diagnostic accuracy across clinically relevant endpoints has not been comprehensively evaluated.
methodsFollowing PRISMA 2020 guidelines, a systematic review and quantitative meta-analysis were conducted using PubMed, Embase, Scopus, and Web of Science through December 2024. Original human studies evaluating Raman, MS, or OCT for intraoperative glioma margin assessment were included. Pooled sensitivity, specificity, and diagnostic odds ratios (DORs) were calculated using a random-effects model. Subgroup analyses addressed tumor versus normal brain tissue, infiltrated versus non-infiltrated margins, and IDH-mutant versus wild-type gliomas.
resultsTwenty-four studies comprising 1768 patients met the inclusion criteria. Across all modalities, pooled sensitivity and specificity were 0.89 (95% CI 0.86-0.92) and 0.88 (95% CI 0.84-0.91), with a pooled DOR of 65.7 (95% CI 42.3-101.8; logDOR 4.18), indicating high overall discriminative performance. Tumor versus normal differentiation achieved DOR 72.4 (logDOR 4.28; I
conclusionsRaman spectroscopy, mass spectrometry, and OCT demonstrate strong diagnostic accuracy for real-time intraoperative glioma evaluation, enabling reliable tissue differentiation and molecular profiling that may enhance resection extent and support precision, molecularly informed neurosurgery.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.